Stock News

Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock
15 Biggest Neuroscience Companies in the World
UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
15 Most Famous Hedge Fund Managers and Their Top Stock Picks
UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Is Biogen Stock a Buy Now?
12 Cheap Biotech Stocks To Buy

As seen on...